Content
02/14/2022
Framingham, MA USA
Variantyx
completed $20 million Series C Round funding. Investors include
GHS Fund (lead), 20/20 HealthCare Partners, IBM Ventures, New Era Capital Partners, Pitango Venture Capital, Quark Venture.
About
Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology.
Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life.
We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect.
Startup
Sector:
MedTech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
